BrightGene Bio Medical Technology C Capital Reinvestment Ratio
BrightGene Bio Medical Technology C capital reinvestment ratio. BrightGene Bio Medical Technology C (688166) has a Capital Reinvestment Ratio of 2.55x as of June 2023, meaning it reinvests 3% of its operating cash flow (CN¥26.70 Million) in capital expenditures (CN¥68.06 Million). See BrightGene Bio Medical Technology C (688166) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of BrightGene Bio Medical Technology C (2016–2024)
Capital reinvestment ratio of BrightGene Bio Medical Technology C from 2016 to 2024. This chart tracks BrightGene Bio Medical Technology C's Capital Reinvestment Ratio across 9 annual periods. See BrightGene Bio Medical Technology C free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
BrightGene Bio Medical Technology C Capital Reinvestment Ratio by Year (2016–2024)
BrightGene Bio Medical Technology C capital reinvestment ratio by year from 2016 to 2024. For the full cash flow conversion analysis, see BrightGene Bio Medical Technology C cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.05x | CN¥245.56 Million | CN¥257.20 Million | ▼ -47.6% |
| 2023 | 2.00x | CN¥194.77 Million | CN¥389.33 Million | ▼ -14.4% |
| 2022 | 2.33x | CN¥311.26 Million | CN¥726.73 Million | ▼ -54.8% |
| 2021 | 5.17x | CN¥176.08 Million | CN¥909.66 Million | ▲ +126.0% |
| 2020 | 2.29x | CN¥155.43 Million | CN¥355.27 Million | ▲ +56.6% |
| 2019 | 1.46x | CN¥61.33 Million | CN¥89.54 Million | ▼ -16.9% |
| 2018 | 1.76x | CN¥63.99 Million | CN¥112.47 Million | ▼ -24.9% |
| 2017 | 2.34x | CN¥35.77 Million | CN¥83.70 Million | ▲ +90.2% |
| 2016 | 1.23x | CN¥29.73 Million | CN¥36.58 Million | — |